Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma

Area of Science:

• Polymer Chemistry
• Materials Science
• Nanotechnology

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options.
• Temozolomide (TMZ) is a standard chemotherapeutic agent for GBM, but its efficacy is often limited by drug stability and resistance.
• Developing novel drug delivery systems can improve TMZ's therapeutic index.

Purpose of the Study:

• To synthesize and characterize polymer-drug conjugates of 2-methacryloyloxyethyl phosphorylcholine (polyMPC) with temozolomide (TMZ).
• To investigate the solution properties, drug stability, and in vitro cytotoxicity of these novel polyMPC-TMZ conjugates.
• To explore the potential of redox-sensitive linkers for enhanced drug release.

Main Methods:

• Synthesis of random and block copolymers of polyMPC and TMZ via reversible addition-fragmentation chain-transfer (RAFT) polymerization.
• Characterization of copolymer nanostructures using dynamic light scattering (DLS) and transmission electron microscopy (TEM).
• Assessment of drug stability through decomposition half-life measurements and evaluation of cytotoxicity in U87MG and T98G glioblastoma cell lines.

Main Results:

• Well-defined nanostructures were observed for polyMPC-TMZ block copolymers.
• Conjugation of TMZ to polyMPC significantly enhanced drug stability, with 2- to 19-fold increases in decomposition half-life compared to free TMZ.
• PolyMPC-TMZ conjugates demonstrated cytotoxicity in both chemosensitive (U87MG) and chemoresistant (T98G) glioblastoma cell lines.
• Redox-sensitive polyMPC-TMZ copolymers were successfully prepared using disulfide linkers.

Conclusions:

• Polymer-drug conjugates based on polyMPC and TMZ offer improved drug stability and sustained release potential.
• These conjugates exhibit promising anti-cancer activity against glioblastoma cells, including resistant strains.
• The developed platform, including redox-sensitive variants, holds potential for advanced glioblastoma therapy.